Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 2.01 1.52% 0.03
XBIO closed up 1.52 percent on Friday, January 18, 2019, on 12 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical XBIO trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 20 DMA Support Bullish 1.52%
Jan 17 Wide Bands Range Expansion 1.52%
Jan 16 Pocket Pivot Bullish Swing Setup -2.43%
Jan 16 Wide Bands Range Expansion -2.43%
Jan 15 Wide Bands Range Expansion 3.08%
Jan 15 Down 3 Days in a Row Weakness 3.08%

Older signals for XBIO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Is XBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.95
52 Week Low 1.37
Average Volume 47,549
200-Day Moving Average 2.596
50-Day Moving Average 2.3687
20-Day Moving Average 1.8788
10-Day Moving Average 2.0105
Average True Range 0.2087
ADX 15.74
+DI 21.315
-DI 18.1405
Chandelier Exit (Long, 3 ATRs ) 1.8739
Chandelier Exit (Short, 3 ATRs ) 2.1261
Upper Bollinger Band 2.234
Lower Bollinger Band 1.5236
Percent B (%b) 0.68
BandWidth 37.811369
MACD Line -0.0915
MACD Signal Line -0.1378
MACD Histogram 0.0464
Fundamentals Value
Market Cap 17.53 Million
Num Shares 8.72 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -1.37
Price-to-Sales 6.14
Price-to-Book 1.60
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.10
Resistance 3 (R3) 2.10 2.07 2.09
Resistance 2 (R2) 2.07 2.05 2.07 2.08
Resistance 1 (R1) 2.04 2.03 2.03 2.04 2.07
Pivot Point 2.01 2.01 2.00 2.01 2.01
Support 1 (S1) 1.98 1.99 1.97 1.98 1.95
Support 2 (S2) 1.95 1.97 1.95 1.94
Support 3 (S3) 1.92 1.95 1.94
Support 4 (S4) 1.92